Advances in Treating mCRPC: Focus on Immunotherapy
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Semantic Scholar
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial - European Urology
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience | Radiation Oncology | Full Text
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors | SpringerLink
ASCO GU 2019: The CHEIRON Study - A Multicentric Phase II Randomized Trial of Docetaxel Plus Enzalutamide versus Docetaxel as First-Line Chemotherapy for Patients with mCRPC
ASCO GU 2020: Overall Survival in Men with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Receiving Bicalutamide Followed by Enzalutamide or Abiraterone
Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel? - Clinical Genitourinary Cancer
Overall Survival (OS) for mCRPC patients treated with docetaxel for a... | Download Scientific Diagram
Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate | Prostate Cancer and Prostatic Diseases
Genomic correlates of clinical outcome in advanced prostate cancer | PNAS
Visceral Metastases and Prostate Cancer Treatment: 'Die Hard,' 'Tough Neighborhoods,' or 'Evil Humors'?
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors - European Urology
Clinical Parameters Predict Overall Survival in mCRPC | PracticeUpdate
Optimal sequencing of commonly used medications for treatment of metastatic castration-resistant prostate cancer - Mayo Clinic
Progression-free survival of mCRPC patients treated with AAP | Download Scientific Diagram
KaplaneMeier estimates of OS from mCRPC diagnosis according to the type... | Download Scientific Diagram
Advances in Treating mCRPC: Focus on Immunotherapy
a) Progression free and b) overall survival probability of patients... | Download Scientific Diagram
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer - Annals of Oncology
ASCO GU 2022: Updated Overall Survival (OS) Analysis for ProCAID: A Randomized, Double Blind, Placebo-Controlled Phase II Trial of Capivasertib with Docetaxel Versus Docetaxel Alone in Metastatic Castration Resistant Prostate Cancer (mCRPC)
